Market Context — Why This Technology, Why Now

The accelerating pace of biomedical research and the expansion of personalized medicine are driving demand for standardized, high-quality tissue preparation. Regulatory bodies are also pushing for greater reproducibility in clinical trials and diagnostics. This technology directly supports these trends by automating a critical pre-processing step, reducing human error, and ensuring consistent sample quality across diverse applications, from drug discovery to advanced cell therapies.

Key Competitive Advantages
01

Simplifies and Standardizes Processing: Connects two syringe devices with a mincing unit, simplifying and standardizing biologic tissue processing while significantly reducing human variability.

02

Minimizes Tissue Damage: Utilizes a unique mechanism to mince tissue within a connected space, suppressing physical stress compared to conventional mechanical methods and contributing to cell viability.

03

Ensures High Reproducibility and Quality: Provides consistently stable mincing quality through an automated, efficient process, significantly improving the reproducibility of results in research and therapy.

Market Opportunity
Regenerative Medicine & Cell Therapy
$3.5B–$7B globally (AI est.)
In stem cell and immune cell therapies, uniform and minimally damaged cell/tissue preparation is crucial for maximizing therapeutic efficacy. This technology significantly enhances the quality and efficiency of this pre-processing step, contributing to improved treatment success rates.
Stem cell therapy developers Immune cell therapy providers Biopharmaceutical companies in cell therapy Contract research organizations (CROs)
Pathology Diagnostics & Research
$200M–$400M domestically (AI est.)
Accurate evaluation of microscopic tissue structures is essential for pathological diagnoses, such as cancer. Uniformly minced tissues produced by this technology contribute to improved diagnostic accuracy and research reproducibility, enabling faster and more precise diagnoses.
Diagnostic pathology laboratories Cancer research centers Academic medical institutions Medical device manufacturers for pathology
Drug Discovery & Preclinical Trials
$1.5B–$3B globally (AI est.)
Standardized processing of animal and cultured tissues enhances the reliability of experimental results in new drug screening and safety evaluation. This technology contributes to the efficiency of research and development and improves data quality, potentially shortening drug discovery timelines.
Pharmaceutical R&D departments Biotechnology companies in drug discovery Contract research organizations (CROs) for preclinical studies Toxicology testing laboratories
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a broad and multifaceted technical scope across 9 claims. Its novelty and inventiveness were objectively recognized after overcoming nine prior art references cited by the examiner, indicating a robust and stable right less susceptible to invalidation.

Competitive White Space

This patent primarily covers the specific syringe-based mincing apparatus. It does not extend to downstream cell separation or upstream tissue collection methods, offering white space for licensees to develop complementary IP in integrated workflows or novel tissue handling solutions.

Economic Impact
~$200K/year estimated cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming this technology reduces the time for biologic tissue mincing from 30 minutes per sample by a skilled technician to 10 minutes. For processing 1,000 samples per month, this could save 2,400 hours annually (200 hours/month × 12 months). With labor costs at ~$35/hour (AI est.), this projects to ~$80K/year (AI est.) in direct labor savings. Additionally, reduced re-processing costs from minimized tissue damage, decreased waste, and improved throughput could lead to a total economic impact of ~$200K/year (AI est.).

Speed to Market
4× faster than in-house development
This technology is already patented, establishing its technical foundation. Developing an equivalent in-house technology from concept design through prototyping, validation, and patent acquisition would typically require at least 4 years. However, licensing this patent could significantly shorten this timeline, enabling market entry in approximately 12 months. The detailed operational principles are described in the patent specification, indicating that major design challenges are already resolved, allowing licensees to optimize development resources for commercialization.
Competitive Positioning

X: Processing Precision & Uniformity
Y: Operability & Efficiency

Business Models & Applications
🔬 Device Sales Model
Directly sell biologic tissue processing devices incorporating this technology to medical institutions, research facilities, and pharmaceutical companies, meeting the demand for high-quality tissue pre-processing.
🤝 Licensing Model
Grant licenses for this patented technology to medical device manufacturers and research equipment manufacturers, generating royalty income. This model could leverage existing sales channels for rapid market penetration.
🧪 Consumables & Service Model
Provide consumables, such as mincing units, alongside the device, as well as value-added services like regular maintenance and technical support, securing continuous revenue streams.
Adjacent Application Opportunities
🍽️ Food Processing
Uniform Processing of High-Functionality Food Ingredients
This technology could uniformly and efficiently mince plant tissues or seaweeds rich in functional components, potentially increasing their value as raw materials for functional foods and supplements. It could contribute to improved extraction efficiency of active compounds and texture adjustment, impacting a global market worth billions.
🌿 Cosmetic Ingredients
Micronization of Natural-Derived Ingredients
The technology could be adapted to uniformly process tissues containing plant or animal-derived beauty ingredients into fine particles suitable for cosmetic formulations. This has the potential to enhance the penetration of active ingredients and improve product stability, addressing a market with over $100B in annual revenue.
🧪 Biofuel & Chemicals
Pre-treatment of Biomass Feedstocks
This technology could be utilized as a pre-treatment device to uniformly mince plant-derived biomass into sizes suitable for fermentation or chemical conversion. This could contribute to improving the efficiency of biofuel production and bioplastic raw material manufacturing, impacting a rapidly growing market projected to reach $200B by 2030.
Integration Roadmap — Estimated 18-Month Deployment
Phase 1: Technical Validation & Requirements
Duration: 3 months
Validate the core principles of this technology against the licensee's existing systems and objectives, defining specific specifications and performance requirements. This includes detailed design for target tissue types and mincing sizes.
Phase 2: Prototype Development & Performance Evaluation
Duration: 6 months
Develop a prototype device based on the defined requirements. Conduct evaluation tests using actual biologic tissues to assess mincing performance, processing time, and tissue damage, followed by optimization.
Phase 3: Mass Production Design & Market Launch
Duration: 9 months
Incorporate performance evaluation results, establish mass production design changes and manufacturing processes. Address relevant regulatory compliance and aim for final product introduction to the market.
Technical Feasibility
This technology features a modular structure based on syringe devices, making integration into existing laboratory environments and medical device systems relatively straightforward. The patent claims explicitly state that the first and second syringe devices are connected by a 'connecting structure,' suggesting high versatility. Composed of general-purpose components and structures, it is estimated that the technical hurdles for incorporating it into existing workflows are low, without requiring extensive capital investment.
Success Scenario
Implementing this technology could significantly reduce the burden of manual labor in biologic tissue mincing, allowing researchers and medical professionals to focus on more advanced analyses and treatments. This is estimated to double the efficiency of cell preparation in regenerative medicine, potentially shortening thousands of cell therapy preparation times annually. As a result, it could accelerate the delivery of treatments to patients and the overall research and development cycle.
Patent Record
APPLICATION NO.
JP2021-150597
REGISTRATION NO.
7778344
FILING DATE
2021/09/15
GRANT DATE
2025/11/21
EXPIRATION DATE
2041/09/15
PATENT HOLDER
学校法人慈恵大学
Examination History
2024-08-08
Request for Examination
2025-06-24
Office Action
2025-08-25
Applicant's Response
2025-08-25
Amendment (Voluntary)
2025-10-28
Decision to Grant